

Synthesis of (7-methoxynaphthalen-2-yl(amino methyl)-1,3,4-thiadiazol-2-yl) phenylazetidin-2-one as anti-inflammatory agents

SANJAY KUMAR[#], AMIT KUMAR^{*}, GAURAV CHIKARA^{*}, GAJENDRA KUMAR, PAWAN KUMAR, RAJIV KUMAR, NUPUR SHISODIA, B.P. YADAV and Y.P. GARG

Department of Chemistry Meerut College Meerut (India).

(Received: September 22, 2009; Accepted: October 21, 2009)

ABSTRACT

N-benzylidene-5-(7-methoxynaphthalene-2-ylamino)methyl)-1,3,4-thiadiazol-2-amine(4a-4e), 3-(5-(7-methoxynaphthalen-2-ylamino)methyl)-1,3,4-thiadiazol-2-yl)-2-phenyl thia-zolidin-4-one (5a-5e) and 3-chloro-1-(5-((7-methoxynaphthalen-2-yl amino)methyl)-1,3,4-thiadiazol-2-yl)-4-phenylazetidin-2-one (6a-6e) have been synthesized in present study. The structures of these newly synthesized compounds were confirmed by their analytical and spectral data. These compounds were also evaluated for their anti-inflammatory, analgesic activities. The compound (6e) was found to exhibit potent anti-inflammatory activity as compared to the standard drugs phenylbutazone. The structures of all compounds have been evaluated by elemental and spectral analysis.

Key words: Naphthalene derivatives, anti-inflammatory, analgesic activities.

INTRODUCTION

Gastrointestinal ulceration/inflammation is the most common toxicity observed with most of the currently used non steroidal anti-inflammatory drugs (NSAIDs). The last decade has seen the development of numerous NSAIDs with different structural classes which could be useful in the treatment of inflammatory diseases. The discovery of Nabumetone¹ exploited the naphthalene nucleus for the synthesis of its derivatives with the hope to possess better activity than Nabumetone. Furthermore, naphthalene derivative have also been found various biological activities like antibacterial² cardiovascular³ and anti-inflammatory⁴⁻¹⁰. The substitution of different heterocyclic nuclei at β -naphthalene has been reported to possess potent anti-inflammatory activities. A large number of thiazolidinones¹¹⁻¹², Azetidinones¹³⁻¹⁴ and thiadiazoles¹⁵⁻¹⁶ were reported to possess potent anti-inflammatory activity. In view above facts it was thought worthwhile to synthesis some newer

naphthalene derivative by incorporating the azetidinone and thiazolidinone moiety at β -position of naphthalene nucleus with the aim to get better molecule with anti-inflammatory activity.

Chemistry

Compound 1, i.e. ethyl 2-(7-methoxynaphthalen-2-ylamino) acetate was prepared by reacting 7-ethoxynaphthalene-2-amine with chloroethylacetate in methanol. Compound 1 was then reacted with thiosemicarbazide in absolute methanol-water to give compound 2, i.e. 2-(2-(7-methoxynaphthalen-2-ylamino) acetyl) hydrazine carbothioamide. Reaction of compound 2 with H₂SO₄ and liquid ammonia in ethanol water to yield compound 3, 5-((7-methoxynaphthalen-2-ylamino) methyl)-1,3,4-thiadiazol-2-amine. On further reaction of compound 3 with various aromatic aldehyde in the presence of glacial acetic acid afforded the corresponding N-benzylidene-5-((7-methoxynaphthalen-2-ylamino) methyl)-1,3,4-thiadiazol-2-amine 4a-4e, further undergoes

cycloaddition with thioglycolic acid in presence of anhydrous $ZnCl_2$ to afford 3-(5-(7-methoxynaphthalen-2-ylamino) methyl)-1,3,4-thiadiazol-2-yl)-2-phenylthiazolidin-4-one 5a-5e. On the other hand, reaction between compounds 4a-4j and chloroacetyl chloride in the presence of 2-3 drops of triethylamine to yielded a cyclized product, i.e. azetidinones 6a-6e, respectively.

RESULTS AND DISCUSSION

All the newly synthesized compounds of this series were tested for anti-inflammatory and analgesic activities at a dose of 50mg/kg.p.o. The results of anti-inflammatory and analgesic activities of all the compounds are statistically significant (Table II).

Out of fifteen compounds only one compound 6b was found to possess more potent anti-inflammatory in the comparison to phenylbutazone. Compound 6b, which was substituted with chloro group at 4 position of phenyl ring have shown 42.80% of inhibition of oedema. Compound 4a, which was possessed phenyl ring have shown least activity i.e 12.25%. The last steps of compounds 6a-6e were characterized by the presence of an azetidinone ring. All the compounds of this stage have shown promising degree (30.60-42.80) of anti-inflammatory activity. Compound 6b, has shown maximum percentage of anti-inflammatory activity i.e 42.80% at a dose of 50mg/kg.p.o. Considering, the potentiality of compound 6b, was study in detail at three graded doses 25, 50, 100mg/kg.p.o. The azetidinone derivatives 6a-6e showed better anti-inflammatory activity than thiazolidinones 5a-5e have shown moderate to good anti-inflammatory activity. Compound 4a-4e, 5a-5e, 6a-6e, and phenylbutazone were tested for their analgesic activity at 50 mg/kg/p.o and the results are given Table II. From the observations it is clear that only one compounds 6c, exhibited better analgesic activity that the standard drug phenyl butazone.

EXPERIMENTAL

General

All melting points were determined in open capillaries with the help of thermonic melting point

apparatus (Campbell Elec-tronic, Mumbai, India), and are uncorrected. All the compounds were routinely checked for their homogeneity by thin layer chromatography (TLC) on silica gel-G (Qualigens Fine Chemicals, Mumbai, India), plates of 0.5 mm thickness and spots were located by iodine (Qualigens Fine Chemicals), eluent was a mixture of benzene (E. Merck, Mumbai, India) and methanol (Qualigens Fine Chemicals) in different proportions. The IR spectra were recorded on FTIR Paragon 500 (Perkin Elmer, Switzerland) and ν in cm^{-1} . The 1H NMR spectra were recorded on Bruker DRX-300 FT NMR instrument (Bruker, Switzerland) in $CDCl_3$ using tetra methyl silane (TMS) as internal reference standard and chemical shift (δ) are reported in parts per million (ppm). The carbon, hydrogen and nitrogen analysis were done on Carlo Erba 1108 elemental analyzer (Carlo Erba Instruments, England) at Central Drug Research Institute, Lucknow, U.P (India).

Synthesis of ethyl 2-(7-methoxynaphthalen-2-ylamino) acetate (1)

A mixture of chloroethylacetate (0.01 mole) in absolute ethanol (50 ml), was added drop-wise during 1h to a well stirred of naphthalen-2-amine 0.01 mole in ethanol. The reaction mixture was stirred for 1 h, and then refluxed for 5h. The excess of solvent was distilled off, cooled, poured onto crushed ice and filtered. The solid thus obtained was recrystallized from ethanol.

Compound 1. m.p 140°C yield 80% IR (KBr) ν_{max} in cm^{-1} : 1250(C-N), 1590(C=C of aromatic ring), 1690(C=O), 3050 (aromatic C-H), 2960 (aliphatic C-H), 3190(N-H), 1H NMR ($CDCl_3$) δ in ppm : 6.90-7.55(m, 7H, Ar-H). 1.35 (t, 3H, $-COOCH_2-CH_3$), 3.28 (s, 3H, Ar- OCH_3), 4.20(2H, $-COOCH_2-CH_3$), 4.60 (d, 2H, NH- CH_2), 5.95 (s, 1H, NH, exchangeable with D_2O). Calc. for $C_{15}H_{17}NO_3$: C, 69.49; H, 6.56; N, 5.40, (Found: C, 69.61; H, 6.57; N, 5.42 %).

Synthesis of 2-(2-(7-methoxynaphthalen-2-ylamino) acetyl) hydrazine carbothio -amide (2)

The mixture of 2-(2-(7-methoxynaphthalen-2-ylamino) acetyl)hydrazine carbo thioamide (0.02 mole) and thiosemicarbazide (0.02 mole) in methanol (50 ml) was refluxed for 10h. After reflexing, excess of solvent was distilled


off and poured into ice. The solid thus obtained was filtered, washed with water and recrystallized from methanol-water.

Compound 2. m.p.130°C, yield 72%, $C_{14}H_{16}N_4O_2S$. IR (KBr) ν_{max} in cm^{-1} : 1260(C-N), 3180(N-H), 3060(aromatic C-H), 1700(C=O), 2950 (aliphatic C-H), 1580(C=C of aromatic ring), 1H N-MR($CDCl_3$) δ in ppm: 7.10-7.50 (m, 7H, Ar-H), 8.10 (m, 4H, NH NH CS NH₂, exchangeable with D₂O), 3.30 (s, 3H, Ar-OCH₃), 4.51(d,2H, NH-

CH₂), 5.75(s,1H,NH exchangeable with D₂O). Calc. for $C_{14}H_{16}N_4O_2S$: C, 55.26; H, 5.26; N, 18.42, (Found: C, 55.40; H, 5.27; N, 18.50 %).

Synthesis of 5-((7-methoxynaphthalen-2-ylamino) methyl)-1,3,4-thiadiazol-2-amine (3)

A mixture of compound 2 (0.02 mole) and conc. H₂SO₄ (20 ml) was kept overnight at room temperature. Then the reaction mixture was poured into cold water and neutralized with liquid ammonia and filtered. The product this obtained was



Scheme 1:

recrystallized from ethanol-water and the purity of product was checked by TLC. Compound **3** : m.p. 145°C, yield 65%, C₁₄H₁₄N₄OS. IR (KBr) ν_{\max} in cm⁻¹ : 3155 (N-H), 3350(NH₂), 2940(C-H aliphatic), 1585(C=C of aromatic ring), 3050(aromatic C-H), 1710(C=O), 1590(C=N), 1220(C-N), 1040(N-N), 735(C-S-C), ¹H-NMR(CDCl₃) δ in ppm: 7.15-7.65(m, 7H, Ar-H), 6.30(bs, 2H, NH₂ exchangeable with D₂O), 3.35 (s, 3H, Ar-OCH₃), 4.58(d, 2H, NH-CH₂), 5.82 (s, 1H, NH, exchangeable with D₂O). Calc. for C₁₄H₁₄N₄OS: C, 58.74; H, 4.89; N, 19.58, (Found: C, 58.94; H, 4.90; N, 19.50 %).

Synthesis of N-benzylidene-5-((7-methoxynaphthalen-2-ylamino) methyl)-1,3,4-thiadiazol-2-amine (4a-4e)

A mixture of compound **3** (0.01 mole) and proper aromatic aldehydes (0.01 mole) in methanol (50 ml) was refluxed for 6h, in presence of few drops of glacial acetic acid. The progress and completion of reaction was monitored by T.LC. The reaction was distilled off, cooled and then poured into crushed ice water and filtered, washed with water and dried. The product thus obtained was recrystallized from suitable solvent, physical and analytical data of compounds 4a-4e are given in Table I

Compound. 4a:m.p. 152°C, yield 70%, IR (KBr) ν_{\max} in cm⁻¹: 3185(N-H), 2945(C-H aliphatic), 1580(C=C of aromatic ring), 3040(aromatic C-H), 1210(C-N), 1045(N-N), 725(C-S-C), ¹H-NMR (CDCl₃) δ in ppm: 7.05-7.76 (m, 11H, Ar-H), 4.62(d, 2H, NH-CH₂), 5.96(s, 1H, NH, exchangeable), 8.10(d, 1H, =CH-Ar), 3.34(s, 3H, Ar-OCH₃).Calc. for C₂₁H₁₈N₄OS: C, 67.36; H, 4.85; N, 14.96, (Found: C, 67.50; H, 4.86; N, 15.02 %).

Synthesis of 3-(5-(7-methoxynaphthalen-2-ylamino) methyl)-1,3,4-thiadiazol-2-yl)-2-phenylthiazolidin-4-one (5a-5e)

To a cold mixture of compound 4a (0.01 mol) in ethanol (50 ml), thioglycolic acid (0.02 mole) was added drop-wise in the presence of anhydrous ZnCl₂ and the reaction mixture was refluxed for 12 h. The reaction mixture were concentrated, cooled and poured into ice water, and filtered. The resulting solid was recrystallised from suitable solvent, physical and analytical data of compounds 5a are given in Table I. Compound 5a. m.p. 135°C, yield 57%, IR (KBr) ν_{\max} in cm⁻¹ : 3180(N-H), 2950(C-H

aliphatic), 1590(C=C of aromatic ring), 3050(aromatic C-H), 1585(C-N), 1205(C-N), 1040(N-N), 735(C-S-C), 1710(C=O), 1490 (C-N of N-CH-Ar) ¹H-NMR (CDCl₃) δ in ppm: 6.90-7.84 (m, 11H, Ar-H), 4.58(d, 2H, NH-CH₂), 6.01(s, 1H, NH, exchangeable), 3.41(s, 3H, Ar-OCH₃), 4.38(d, 1H, =CH-N), 2.85(s, 2H, CH₂). Calc. for C₂₃H₂₀N₄O₂S₂ C, 61.59; H, 4.14; N, 12.49, (Found: C, 61.71; H, 4.51; N, 12.55 %).

Synthesis of 3-chloro-1-(5-((7-methoxynaphthalen-2-ylamino) methyl)-1,3,4-thiadiazol-2-yl)-4-phenylthiazolidin-2-one (6a-6e)

To a solution of compound 4a (0.01 mol) in absolute ethanol (100 ml) 2-3 drops of triethylamine and chloroacetylchloride (0.02 mole) were added under stirring 1 h. The reaction mixture were stirred and refluxed for 10 h. After refluxing, these reaction mixtures were distilled off, cooled and poured onto ice. Solid thus obtained was filtered and recrystallized from suitable solvent, physical and analytical data of compounds (6a-6e) are given in Table I.

Compound 6a

m.p. 133°C, yield 55%, .IR (KBr) ν_{\max} in cm⁻¹ : 3180(N-H), 2950 (C-H aliphatic), 1585 (C=C of aromatic ring), 3050 (aromatic C-H), 1610(C-N), 1215 (C-N), 1050 (N-N), 1710 (C=O), 690 (C-Cl). ¹H NMR (CDCl₃) δ in ppm: 7.10-7.80 (m, 11H, Ar-H), 4.55(d, 2H, NH-CH₂), 5.95(s, 1H, NH, exchangeable), 3.39(s, 3H, Ar-OCH₃), 6.42 (d, 1H, =CH-Cl), 4.42(d, 1H, CH-N). Calc. for C₂₃H₁₉ClN₄O₂S : C, 61.26; H, 4.25; N, 12.42, (Found: C, 61.23; H, 4.24; N, 12.35 %).

Biological Studies

The experiment were performed with albino rats of Charles-Foster strain of either sex, excluding pregnant females, of 60 to 90 days weighing 90-120 g. Acute toxicity was tested in albino mice (15-29g). Food (Chaw pallet) and water was given to the animals ad libitum. The compounds were dissolved in propylene glycol.

Anti-inflammatory activity against carrageenan-induced rat's paw oedema

This study was done by following the procedure of Winter *et al.*¹⁷. The rats were divided into three groups (control, drug treated, and standard, drug of six animals each. A freshly

Table 1: Physical and analytical data of compound (4a-4e), (5a-5e) and (6a-6e)

Compd. No.	R	m.p. (°C)	Yield %	Recrystallization solvent	Molecular Formula	Elemental Analysis					
						%C		%H		%N	
						Calcd	Found	Calcd	Found	Calcd	Found
4a	C ₆ H ₅	152	70	Ethanol	C ₂₁ H ₁₈ N ₄ O ₂ S	67.36	67.50	4.85	4.86	14.96	15.02
4b	4-ClC ₆ H ₄	131	65	Acetic-Acid	C ₂₁ H ₁₇ ClN ₄ O ₂ S	61.68	61.80	4.19	4.20	13.70	13.76
4c	4-OHC ₆ H ₄	165	58	Ethanol	C ₂₁ H ₁₈ N ₄ O ₂ S	64.60	64.72	4.65	4.66	14.35	14.29
4d	4-CH ₃ C ₆ H ₄	142	55	Methanol	C ₂₂ H ₂₀ N ₄ O ₂ S	68.02	68.18	5.19	5.18	14.42	14.48
4e	4-OCH ₃ C ₆ H ₄	138	60	DMG	C ₂₂ H ₂₀ N ₄ O ₂ S	65.33	65.46	4.98	4.99	13.85	13.90
5a	C ₆ H ₅	135	57	Acetone	C ₂₃ H ₂₀ N ₄ O ₂ S ₂	61.59	61.71	4.49	4.51	12.49	12.55
5b	4-ClC ₆ H ₄	141	53	Methanol	C ₂₃ H ₁₉ ClN ₄ O ₂ S ₂	57.19	57.06	3.96	3.95	11.60	11.53
5c	4-OHC ₆ H ₄	132	55	Ethanol	C ₂₃ H ₂₀ N ₄ O ₂ S ₂	59.46	59.55	4.36	4.37	12.06	12.12
5d	4-CH ₃ C ₆ H ₄	103	60	Acetic-Acid	C ₂₄ H ₂₂ N ₄ O ₂ S ₂	62.31	62.45	4.79	4.80	12.11	12.19
5e	4-OCH ₃ C ₆ H ₄	127	62	Ethanol	C ₂₄ H ₂₂ N ₄ O ₂ S ₂	60.23	60.36	4.63	4.64	11.71	11.75
6a	C ₆ H ₅	133	55	Methanol	C ₂₃ H ₁₉ ClN ₄ O ₂ S	61.26	61.13	4.25	4.24	12.42	12.35
6b	4-ClC ₆ H ₄	145	50	DMG	C ₂₃ H ₁₇ Cl ₂ N ₃ O ₂ S	60.80	60.95	3.77	3.78	9.25	9.30
6c	4-OHC ₆ H ₄	125	48	Ethanol	C ₂₃ H ₁₈ ClN ₃ O ₂ S	63.37	63.50	4.16	4.15	9.64	9.60
6d	4-CH ₃ C ₆ H ₄	116	40	Acetic-Acid	C ₂₄ H ₂₀ ClN ₃ O ₂ S	66.43	66.55	4.65	4.66	9.68	9.75
6e	4-OCH ₃ C ₆ H ₄	109	45	Benzene	C ₂₄ H ₂₀ ClN ₃ O ₂ S	64.06	64.20	4.48	4.50	9.34	9.40

Table 2: Biological data of compounds (4a-4e), (5a-5e), and (6a-6e)

Compounds	R	Anti-inflammatory activity		Analgesic activity	
		Dose (mg/kg p.o.)	% oedema inhibitor relation	Dose (mg/ kg / p.o)	% protection
4a	C ₆ H ₅	50	12.25	50	10.15
4b	4-ClC ₆ H ₄	50	20.32	50	18.18
4c	4-OHC ₆ H ₄	50	14.48	50	12.52
4d	4-CH ₃ C ₆ H ₄	50	16.19	50	14.27
4e	4-OCH ₃ C ₆ H ₄	50	18.44	50	16.22
5a	C ₆ H ₅	50	21.65	50	19.98
5b	4-ClC ₆ H ₄	50	23.66	50	21.62
5c	4-OHC ₆ H ₄	50	25.78	50	23.13
5d	4-CH ₃ C ₆ H ₄	50	16.17	50	24.05
5e	4-OCH ₃ C ₆ H ₄	50	28.02	50	26.34
6a6b	C ₆ H ₅ 4-ClC ₆ H ₄	50	30.60	50	28.28
		25	25.75	25	20.12
		100	68.21	100	60.84
6c	4-OHC ₆ H ₄	50	34.88	50	31.08
6d	4-CH ₃ C ₆ H ₄	50	31.50	50	29.72
6e	4-OCH ₃ C ₆ H ₄	50	32.10	50	27.60
		25	26.76	25	14.26
		50	36.80	50	32.50
		100	64.68	100	54.58

*P < 0.05, **P < 0.01, ***P < 0.001.

Propylene glycol standard for control group.

prepared suspension of carrageenan (1% in 0.9% saline). 0.05 ml was injected under the planter aponeurosis of the right hind paw of each rat. Test compounds and standard drug were administered orally to the animals of drug treated groups and the standard drug group, respectively. 1 h before the carrageenan injection. The paw volume of each rat was measured before 1 and after 3 h of carrageenan treatment with the help of a plethymometer. The percent anti-inflammatory activity was calculated according to the formula given below-

$$\text{Percentage of inhibition of oedema} = (1 - V_t/V_c) \times 100$$

Where, V_t and V_c are the mean increase in paw volume of rats of the treated and the control group, respectively. Results obtained were statistically analyzed.

Analgesic activity

This activity was performed by following the method of Berkowitz *et al*¹⁸. This method is based on the property of the test compound to antagonize the phenyl quinone-induced pain syndrome in mice. Groups of five mice were injected intraperitoneally with 0.25 ml of a 0.02% solution of phenylquinone in ethanol (5%) 1 h after of oral administration of the test compound. The number of writhes induced in each mouse was counted for 5 min (between 5 and 10 min) after injection of an irritant. The analgesic effect was expressed as percent protection in comparison to control.

$$\% \text{ Protection} = (1 - \text{mean no. of writhes in mice of test groups} / \text{mean number of writhes in mice of control group}) \times 100$$

REFERENCES

1. Roberts. L.J., Morrow J.D. in Goodman and Gilman's. The pharmacological Basis of therapeutics Mc graw Hill, New York, 687 (2001).
2. Hodges, S.J. *chem. Abstr.* **128**(9): 562 (1998).
3. Singh, R. Panday, V.K. Srimal, R.C, and Das, P.R, *Acta Pharm*, **43**(3): 195 (1993).
4. Sharma, S, Singh T, Mittal R, Saxena K.K., Srivastava. V.K, Kumar A, *Arch Pharm. Chem. Life Sci.* **339**: 145 (2006).
5. Sharma S, Srivastava. S.K and Kumar A *Arzneim- Forsch./Drug Res.* **53**(1): 44 (2003).
6. Mohammad, A. Oberoi, A, and Shah, A, *Ind. J.Chem.* **38B**(2): 237 (1999).
7. Chih-Hua, T, Tseng-Sheng, L, Pin-Keng, S, Lo-Ti, T, Jih-Pyang, W, Chih-Mei, C, Cherng-Chyi, T, Yeh-Long, C, *Bio-Organic J. Med. Chem.* **17**: 18, 6773 (2009).
8. Bansal E., Srivastava V.K., Kumar Ashok *Eur. J.Med. Chem.* **36**: 81 (2001).
9. Udipi R.H, Kushnoor A.H., Bhat A.R, *Ind. J.Herercyclic Chem.* **8**: 63 (1999).
10. Bansal E , Srivastava V.K., and Kumar Ashok, *Arzneim- Forsch/Drug Res* **50**(II): 11, 1009 (2000).
11. Srivastava S.K., Yadav R. and Srivastava S.L., *Ind. J.Chem*, **42B**: 399 (2004).
12. Takagi, Masae, Ishimitsu, Reiichi, Nishike *Tadayuki Chem. Abstr.* **135**: 288773 f (2001).
13. Agarwal, R, Agarwal, C.Singh C. *Ind. J.Chem* **28B**: 8999 (1989).
14. Bansal, E., Kumar, A., *Orient. J. Chem.* **5B**: 489 (1999).
15. Srivastava S.K., Srivastava S., Srivastava S.D. *Ind. J.Chem* **38B**: 183 (1999).
16. B.R.Rani, U.T.Bhalerao, M.F.Rahman *Ind. J.Chem* **29B**: 995 (1990).
17. Winter CA, Edwin AR and George WN. *Procsoc Exptl Biol*, **3**: 544 (1962).
18. Berkiwitz B.A., Finck A.D., Ngai S.H., *J. Pharmacol. Exp. Ther.* **203**: 539-547 (1997).